First Interstate Bank increased its position in shares of Inovio Pharmaceuticals, Inc. (NASDAQ:INO) by 291.9% during the third quarter, according to its most recent filing with the Securities & Exchange Commission. The fund owned 24,300 shares of the biopharmaceutical company’s stock after buying an additional 18,100 shares during the quarter. First Interstate Bank’s holdings in Inovio Pharmaceuticals were worth $154,000 as of its most recent SEC filing.

A number of other large investors have also recently added to or reduced their stakes in the stock. Wasatch Advisors Inc. grew its stake in shares of Inovio Pharmaceuticals by 3.1% in the 3rd quarter. Wasatch Advisors Inc. now owns 2,691,331 shares of the biopharmaceutical company’s stock valued at $17,063,000 after purchasing an additional 80,513 shares during the last quarter. Bank of New York Mellon Corp grew its stake in shares of Inovio Pharmaceuticals by 17.4% in the 3rd quarter. Bank of New York Mellon Corp now owns 382,206 shares of the biopharmaceutical company’s stock valued at $2,423,000 after purchasing an additional 56,623 shares during the last quarter. New York State Common Retirement Fund grew its stake in shares of Inovio Pharmaceuticals by 17.1% in the 3rd quarter. New York State Common Retirement Fund now owns 127,943 shares of the biopharmaceutical company’s stock valued at $811,000 after purchasing an additional 18,672 shares during the last quarter. Swiss National Bank grew its stake in shares of Inovio Pharmaceuticals by 22.0% in the 3rd quarter. Swiss National Bank now owns 138,700 shares of the biopharmaceutical company’s stock valued at $879,000 after purchasing an additional 25,000 shares during the last quarter. Finally, Keybank National Association OH grew its stake in shares of Inovio Pharmaceuticals by 41.6% in the 3rd quarter. Keybank National Association OH now owns 42,820 shares of the biopharmaceutical company’s stock valued at $271,000 after purchasing an additional 12,578 shares during the last quarter. Hedge funds and other institutional investors own 26.44% of the company’s stock.

COPYRIGHT VIOLATION WARNING: This story was first reported by Daily Political and is the property of of Daily Political. If you are accessing this story on another website, it was illegally stolen and republished in violation of United States and international copyright & trademark laws. The original version of this story can be viewed at https://www.dailypolitical.com/2017/11/22/first-interstate-bank-grows-position-in-inovio-pharmaceuticals-inc-ino.html.

Inovio Pharmaceuticals, Inc. (INO) traded down $0.07 during midday trading on Wednesday, hitting $4.57. The stock had a trading volume of 349,819 shares, compared to its average volume of 1,277,852. Inovio Pharmaceuticals, Inc. has a 12 month low of $4.20 and a 12 month high of $9.86.

Inovio Pharmaceuticals (NASDAQ:INO) last released its earnings results on Wednesday, November 8th. The biopharmaceutical company reported ($0.40) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.25) by ($0.15). The business had revenue of $2.60 million during the quarter, compared to analyst estimates of $10.27 million. Inovio Pharmaceuticals had a negative net margin of 221.55% and a negative return on equity of 72.19%. The business’s revenue for the quarter was down 79.2% compared to the same quarter last year. During the same quarter in the previous year, the company posted ($0.28) earnings per share. equities research analysts anticipate that Inovio Pharmaceuticals, Inc. will post -1.12 EPS for the current year.

A number of analysts recently weighed in on the company. HC Wainwright restated a “buy” rating and issued a $13.00 price target on shares of Inovio Pharmaceuticals in a research note on Thursday, November 9th. Maxim Group restated a “buy” rating and issued a $12.00 price target on shares of Inovio Pharmaceuticals in a research note on Tuesday, September 12th. ValuEngine downgraded Inovio Pharmaceuticals from a “sell” rating to a “strong sell” rating in a research note on Thursday, November 9th. Zacks Investment Research downgraded Inovio Pharmaceuticals from a “hold” rating to a “sell” rating in a research note on Monday, November 13th. Finally, BidaskClub upgraded Inovio Pharmaceuticals from a “sell” rating to a “hold” rating in a research note on Saturday, September 9th. Three analysts have rated the stock with a sell rating, two have assigned a hold rating and eight have assigned a buy rating to the stock. The company has an average rating of “Hold” and a consensus price target of $19.16.

Inovio Pharmaceuticals Profile

Inovio Pharmaceuticals, Inc (Inovio) is a clinical-stage pharmaceutical company, which is involved in developing deoxyribonucleic acid (DNA) immunotherapies and vaccines focused on treating and preventing cancers and infectious diseases. The Company’s DNA-based immunotherapies, in combination with its electroporation delivery devices, generates immune responses, in particular T cells, in the body to fight target diseases.

Institutional Ownership by Quarter for Inovio Pharmaceuticals (NASDAQ:INO)

Receive News & Ratings for Inovio Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Inovio Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.